Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies

NCT03366350 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
B Cell Lymphoma

Interventions

PROCEDURE: Allogeneic hematological stem cell transplantation

Sponsor

Wuhan Sian Medical Technology Co., Ltd

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]